Incyte Corporation (INCY)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with INCY?
Powered by Yahoo ScoutIncyte Corporation is gaining attention ahead of significant ESMO data for its KRAS G12D inhibitor, with recent earnings showing strong revenue growth. Despite mixed market views on valuation, the company's upcoming data presentations could impact its competitive position in oncology.
- Previous Close
128.00 - Open
126.46 - Bid --
- Ask --
- Day's Range
126.04 - 128.04 - 52 Week Range
81.09 - 132.60 - Volume
-- - Avg. Volume
-- - Market Cap (intraday)
25.692B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Recent News
Statistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (5yr expected)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
--
-
Return on Assets (ttm)
--
-
Return on Equity (ttm)
--
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
--
-
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
-
Total Cash (mrq)
--
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
--
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
